Background: In sub-Saharan Africa (SSA), the highly albumin-bound b-lactam ceftriaxone is frequently used for the empirical treatment of severe bacterial infections. Systemic drug exposure of b-lactams can be altered in critically ill ICU patients, but pharmacokinetic and pharmacodynamic data for non-ICU SSA populations are lacking.
Introduction
In sub-Saharan African (SSA), a region of the world with high HIV infection rates, 10%-34% of patients admitted with fever suffer from bacterial bloodstream infections or sepsis. [1] [2] [3] A high proportion of these infections are caused by Streptococcus pneumoniae and non-typhoidal Salmonella serovars and mortality rates can be as high as 46%-72%. 4, 5 The third-generation cephalosporin ceftriaxone is among the most frequently used antibiotics for the empirical treatment of adults in this situation.
Evidence from resource-rich ICU settings suggests that appropriateness of antibiotic treatment should not only be reviewed in terms of antibiotic drug choice but also in terms of systemic drug exposure. 6, 7 Pharmacokinetics (PK) of antibiotics in critically ill patients can be substantially altered. b-Lactam antibiotics are particularly vulnerable, as they are hydrophilic drugs with renal CL as the predominant route of elimination. Unlike most b-lactams, ceftriaxone is highly bound to albumin (85%-95%) at therapeutic concentrations. During sepsis and hypoalbuminaemia a lower protein-bound drug fraction, an increased volume of distribution (V) and increased CL may change the total as well as the unbound, active drug concentration. 6, 7 Such alterations may give rise to an inability to attain pharmacodynamic (PD) targets, including the increasingly promoted PD target of the unbound drug concentration remaining above the MIC throughout the dosing interval (fT .MIC " 100%). 8 Ultimately, underexposure may lead to adverse clinical outcome. 9, 10 In SSA, highly prevalent chronic diseases such as TB, hepatitis B and hypertension also have the potential to influence the PK of antibiotics by means of cachexia and liver and kidney dysfunction. [11] [12] [13] How coinciding acute and chronic conditions in severely ill (non-ICU) SSA patients influence the PK of b-lactam antibiotic drugs, including ceftriaxone, has been poorly investigated. What is clear is that underexposure to the unbound drug may not only pose a threat to an individual patient's health, but also to public health, as it contributes to the emergence of antimicrobial resistance, a phenomenon that is already highly prevalent in SSA countries. 14, 15 In view of the above, we performed a population PK (PPK) study of ceftriaxone in a Mozambican, adult hospital medicine ward population. The specific aims of the study were to describe the PPK of unbound ceftriaxone (CEF u ) and total ceftriaxone (CEF t ) in order to identify sources of PK parameter variability. Additionally, we aimed to assess the probability of PK/PD target attainment (PTA) of CEF u for the treatment of bacterial pathogens commonly causing sepsis in SSA.
Methods

Setting
The Beira Central Hospital (HCB) is a Mozambican governmental referral health facility. The proportion of patients infected with HIV on its medicine ward may be as high as 74% and up to 32% of patients may die during their hospital stay. 16 
Study design
The current study was a prospective, observational PPK study of ceftriaxone, as part of a PPK study of commonly used antibiotics among patients admitted to the HCB medicine ward. In this study, PK data were collected from October 2014 until November 2015 from patients who were treated with intravenously administered ceftriaxone. The study was reviewed and approved by the Mozambican National Committee for Bio-ethics in Health (CNBS: study registration no. 118/CNBS/2013). Additionally, a letter of approval was obtained from the HCB director. Participants gave written informed consent. Those unable to read, write and/or understand Portuguese gave a thumbprint and an impartial, literate witness observed the entire informed consent process and subsequently co-signed the informed consent form.
Recruitment and data collection
Patients were eligible for study entry if they were hospitalized on the HCB medicine ward while being treated with ceftriaxone as prescribed by an HCB physician, and as documented in a patient's medication record. Any ceftriaxone dosing regimen that was allowed for use by the Mozambican National Institute of Health (INS) was accepted. 17 Inclusion criteria were age !18 years and being willing and able to give informed consent. Exclusion criteria were the use of drugs known to significantly affect the PK of the study antibiotics (probenecid, phenylbutazone, acetylsalicylic acid and indomethacin), a haemoglobin level 6 g/dL as measured by the HCB laboratory (haemoglobin safe limit adapted from the North Shore Human Subject Protection Program Guidance Document on maximum blood draw limits 18 ), any condition necessitating a blood transfusion irrespective of haemoglobin level, and an altered level of consciousness.
Two trained research nurses captured baseline characteristics and ceftriaxone dosing information, and measured the body weight and height of all study participants. Doses of 1 g of ceftriaxone powder for injection (Nirlife, Nirma Ltd, Gujarat, India) were dissolved in 10 mL of sterile water for injection and subsequently injected intravenously via a venous catheter in half a minute, according to the responsible physician's prescription. Over a time period of two or more days, a maximum of four blood samples were collected for ceftriaxone concentration measurement. Sample times were pre-dose (trough level), 30-120 min after intravenous administration (peak level) and two random timepoints during the dosing interval (random levels). Ceftriaxone administration procedures were observed where possible and a maximum of 19 mL of blood was collected. One blood sample was also used for the measurement of albumin, AST, ALT, GGT and creatinine concentrations. Bilirubin levels were not measured for practical reasons in relation to bilirubin's high photosensitivity. CL CR was estimated using the Cockcroft and Gault formula. 19 Sample handling and drug assay EDTA anti-coagulated blood samples were refrigerated at 4-8 C immediately after collection until laboratory processing, which took place within two hours of collection. Samples were centrifuged and plasma was stored at #80 C in the local research laboratory until shipment on dry ice to the Netherlands for biochemical marker and drug concentration analysis.
Plasma was ultrafiltrated (centrifugal filters: Millipore Amicon Ultra 0.5 mL/30K, Merck Millipore, Darmstadt, Germany) and the ultrafiltrated plasma was subsequently processed as a typical plasma sample to obtain the unbound concentration. CEF t and CEF u concentrations were measured using validated HPLC MS (LC: LC30 UPLC, Shimadzu, Kyoto, Japan; MS: QTRAP 5500 system, Sciex, Framingham, MA, USA). The lower limit of quantification (LLQ) was 1 mg/L and the higher limit of quantification was 40 mg/L. Concentrations higher than this were diluted and re-analysed. Within-and between-assay variability was lower than 5.6% and 6.8%, respectively. The accuracy of the assay was between 90% and 105%.
PPK analysis
Model development
The PPK analysis was performed using the non-linear mixed-effect modelling software package NONMEM (7.1.2; Icon Development Solutions, Ellicott City, MD, USA). Model building was performed using a stepwise approach. During a first step, a structural, compartmental PPK model was developed in which the PK of CEF u and CEF t as well as protein binding of ceftriaxone were described, including their between-patient variability (BPV). In the second step, an attempt was made to explain BPV by building a covariate model in which patient demographics and pathophysiological factors were tested for their correlation with the estimated PK parameters. In the third and last step, the robustness and validity of the final model resulting from the second step were tested.
Structural model
One-and two-compartment models were tested. Estimated PK parameters were V, CL and, in the case of testing of a two-compartment model, peripheral V and intercompartmental CL. BPV of V and CL was estimated exponentially. 20 Modelling of ceftriaxone protein binding and CEF t was done using linear and non-linear protein-binding models, according to the following equation: The residual variability (i.e. the difference between measured CEF u and CEF t concentrations and the corresponding CEF u and CEF t concentrations Ceftriaxone PK/PD in sub-Saharan African patients JAC predicted by the model) was modelled with additive or proportional models or a combination of both. The so-called M3 method was used for the handling of CEF t and CEF u concentrations below the LLQ. 22 
Covariate model
Tested covariates included age, sex, weight, height, BMI, CL CR and haemoglobin, albumin, creatinine, GGT, ALT and AST concentrations. All covariates were screened for the significance of the correlation between the covariate and the PK parameter by univariate analysis, using a P value cut-off of 0.05. Furthermore, a reduction in BPV or residual variability, as well as biological plausibility of a covariate-PK parameter relationship was used as a criterion for covariate selection. All covariates selected during the univariate analysis subsequently entered an intermediate model for a backward elimination procedure (multivariate analysis) with a cut-off for statistical significance of 0.001, which yielded the final model.
Potential improvement of the model by adding a compartment or by introducing a correlation between a covariate and a PK parameter was evaluated using the likelihood ratio test, in which the difference between the minimum objective function value (OFV) generated by NONMEM V R for two hierarchical models is determined. Improvement in model fit was defined as an OFV decrease of !3.8 units while using a v 2 distribution with one degree of freedom, corresponding to a P value cut-off of 0.05. For the backward elimination covariate procedure an OFV decrease of !10.8 units was used. Model performance was also evaluated by visual inspection of diagnostic 'goodness-of-fit' plots. 23 These were generated using Pirana (version 2.9.0) and Xpose (version 4.3.2) software (Uppsala Pharmacometrics, Uppsala, Sweden).
24,25
Model robustness and predictive performance
The robustness of the parameter estimates from the final model resulting from the second step was tested using a bootstrap analysis. In this analysis, the dataset was resampled 1000 times. Based on 1000 simulations, visual predictive checks (VPCs) investigated whether the final model could adequately predict the observed time course of CEF u and CEF t , including the observed variability. Bootstrap and VPC analyses were performed using Perl-speaks-NONMEM (PsN) version 3.5.3 software (Uppsala Pharmacometrics, Uppsala, Sweden). 26 
Monte Carlo dosing simulations
Using the final PPK model, CEF u concentration-time profiles were predicted based on Monte Carlo simulations following three dosing regimens: 1 g twice daily (q12h), 2 g once daily (q24h) and 2 g q12h. Each simulation generated concentration-time profiles for 1000 virtual patients per drug regimen. Based on these data, the PTA, being the percentage of patients with a CEF u remaining above a specified MIC during a specified percentage of time of the dosing interval (fT .MIC ), was calculated for different fT .MIC targets.
The primary target to be tested was fT .MIC " 50% and the secondary target was fT .MIC " 100%. The choice of PD targets was based on conclusions of recent reviews concerning b-lactam administration and PD targets in critically ill patients. 6, 8, 10 The choice of the target MIC was based on the EUCAST MIC clinical breakpoints for susceptibility to ceftriaxone of Enterobacteriaceae (1 mg/L) and S. pneumoniae (0.5 mg/L). 27 
Results
Patients and ceftriaxone concentrations
We screened 762 patients for the larger PPK study and excluded 366 patients (Figure 1 ). The most common reason for exclusion was a haemoglobin level 6 g/dL. We included 98 patients in the current study on ceftriaxone and 88 participants remained for analysis. A large majority (93.1%) had a 1 g q12h ceftriaxone dosing schedule. Patient characteristics are presented in Table 1 .
A total of 277 plasma samples yielded 277 CEF t and 276 CEF u concentrations. Fewer than four plasma samples were available for 43/88 (48.9%) participants, with the most common explanation being a participant's unforeseen discharge (Figure 1) . Three or four plasma samples were available for analysis for 67/88 (76.1%) participants. There were 33/276 (12%) CEF u samples with a concentration below the LLQ. The median unbound fraction was 19% (IQR " 13-29). The observed CEF t and CEF u concentrations are shown in Figure 2 .
PPK analysis Structural model
During step one of the analysis, CEF u data were fitted to several compartmental models and a one-compartmental model best fitted the data, with the difference in OFV between a one-and a two-
Patients excluded: n =366 Additionally, the residual error dropped from 13.1 mg/L to 9.8 mg/ L and non-linear protein binding therefore best described CEF t concentration and protein binding (Figure 3) . K m was estimated to be 0.01 mmol/L while B max was 0.11 mmol/L. The estimated BPV for B max was 31% (Table 2) .
Covariate model
The multivariate covariate analysis, based on 100% availability of covariate results, yielded a model with significant associations between CEF u CL and CL CR as well as between B max and albumin concentration, as shown by
With these associations in the model, the BPV of CEF u CL decreased from 93% to 77%, although a substantial part of the BPV in CEF u CL remained unexplained ( Table 2 ). The BPV of B max could, however, no longer be reliably estimated. Using the B max and albumin concentration equation This relationship between CEF t concentrations and the observed and predicted CEF u concentrations is shown in Figure 4 .
Model robustness and predictive performance
The final model had an adequate fit as shown by the VPC (Figure 2 ). The maximum relative standard error (RSE) with which parameters could be estimated was 41% and bootstrap estimations were similar to the ones from the final model ( Table 2 ). The residual variability, an estimate of unexplained variability relating to measurement error, errors in data collection, intra-patient variability and model misspecification, was 9.9 mg/L (" 0.015 mmol/L; RSE 12%) for the CEF u concentration and 24 mg/L (" 0.036 mmol/L; RSE 6%) for the CEF t concentration (Table 2) .
Monte Carlo dosing simulations
For the dosing regimens investigated, patients with a higher CL CR and lower albumin concentrations had lower CEF t concentrations (Figure 5a and c) . As for CEF u , simulations indicated that only a higher CL CR was projected to be leading to lower CEF u concentrations (Figure 5b and d) .
For microorganisms with an MIC of 1 mg/L, the PTA of the 1 g q12h ceftriaxone regimen for patients with the median CL CR of 91 mL/min was 95.1% for the primary PD target of fT .MIC " 50% ( Figure 6 ). The PTA of the secondary PD target of fT .MIC " 100% was 58.2%. In the case of a 2 g q24h ceftriaxone regimen, the PTA was 74.8% and 16.5% for the PD targets of fT .MIC " 50% and fT .MIC " 100%, respectively. When treating a pathogen with an MIC of 0.125 mg/L, the PTA of the fT .MIC " 50% PD target was 99.9% for a 1 g q12h regimen and 96.5% for a 2 g q24h ceftriaxone regimen in patients with a median albumin concentration of 29 g/L and median CL CR . The respective PTAs were 94.5% and 52.2% when the fT .MIC " 100% target was applied ( Figure 6 ).
Discussion
The present study describes the development of a PPK model of ceftriaxone in an adult SSA hospital population with presumptive severe infection, based on observed CEF u and CEF t plasma concentrations. Ceftriaxone PK/PD in sub-Saharan African patients
JAC
The study population was generally young and severely ill, as illustrated by its low median BMI and low median haemoglobin and albumin concentrations. A one-compartment model with non-linear protein binding best described CEF t /CEF u PK. Similar to other studies with ICU patients, the BPV of PK parameters was high, with the BPV of CEF u CL being as high as 77% in the final model. As can be expected with an antibiotic with renal CL as the predominant route of elimination, CEF u CL was significantly associated with CL CR and explained a substantial part of this BPV. 28, 29 Non-linear, saturable protein binding of ceftriaxone has been suggested by others as well. 30, 31 The relationship between the maximum ceftriaxone concentration bound to albumin (B max ) and albumin concentration as found in our study implies that B max is lower at lower albumin concentrations. In agreement with this, the observed low median albumin concentration of 29 g/L corresponded to a median CEF u fraction of 19% which is high relative to what can be expected under normal albumin concentrations at therapeutic concentrations (5%-15%). Thus, with a higher CEF u Bos et al.
fraction present at such lower albumin concentrations, more CEF u will be available for CL. At steady-state, such increased CL leads to a lower CEF t concentration that is also less representative of the CEF u concentration. 30 Our findings match the results from earlier PK studies of ceftriaxone in non-SSA ICU patients that implied predominant dependency of CEF u exposure on CL CR . 28, 29, 32, 33 However, only one study suggested an inability to reach the fT .MIC " 100% target with a 2 g q12h prescription. 32 This may be explained by the fact that not all studies based their conclusions on measured CEF u concentrations and that some may have been too small to draw meaningful conclusions.
Although none of the measured liver enzymes proved to have a significant relationship with CEF u PK, other investigators have found bilirubin levels to be negatively correlated with albumin binding and non-renal CL of CEF u .
28,34 Since we did not include bilirubin in our analysis, it cannot be excluded that part of the BPV may have resulted from a relationship between liver function and CEF u PK that was left unaccounted for.
For a 2 g q24h dosing regimen, the PTA for the PD target of fT .MIC " 100% was just above 50% for pathogens with an MIC of 0.125 mg/L. Importantly, simulations also demonstrated that the use of the more commonly prescribed 1 g q12h ceftriaxone regimen may lead to CEF u underexposure as well, especially for patients with preserved kidney function. The risk for underexposure in patients with impaired renal function appears to occur mostly when stringent PD targets are applied. For pathogens with an MIC of 1 mg/L, both q24h and q12h dosing are likely to lead to CEF u underexposure. Although clinical and microbiological evidence is still limited, available data do seem to support the idea that in patients with severe disease, who may be at risk for impaired drug distribution and tissue penetration, the use of a more stringent PD target, such as fT .MIC " 100%, improves clinical outcome and reduces the emergence of antimicrobial resistance, compared with the most conservative target of fT .MIC " 50%. 8, 10, 35, 36 The CEF u concentration-time simulations could not be tested against the background of locally derived bacterial MICs, which means that the actual PTA could differ from the ones suggested on the basis of the MIC used for Enterobacteriaceae and S. pneumoniae (1 mg/L). Results from a surveillance study of global antimicrobial susceptibility showed that in Africa, 32% of S. pneumoniae isolates collected from 2009 to 2012 were resistant to penicillin (MIC .2 mg/L), and that in this group, roughly 25% of isolates were non-susceptible to ceftriaxone (MIC .1 mg/L). 37 MDR of non-typhoidal Salmonella serovars, including resistance to third-generation cephalosporins, is emerging. Third-generation cephalosporin resistance still appears to be restricted to certain geographical areas, but very limited African susceptibility surveillance data are currently available. 38 There are limitations to our study. Firstly, we did not collect information about a patient's fluid balance and the presence of excess fluid in the interstitial and transcellular space, and are therefore not informed about how hydration status, oedema and 'third spacing' may have affected PK BPV. It is our experience that administration of sufficient amounts of fluids in adult hospitalized patients in resource-poor settings is rare and our observations are supported by reports about patients with presumptive sepsis from Uganda. 39, 40 An inadequate hydration status in a substantial amount of cases may imply that CEF u concentrations as well as PTAs could turn out to be lower than what was found in the current study once proper volume therapy is applied.
Secondly, the Cockcroft and Gault formula's predictive value is limited in critically ill patients without stable renal function. Although this formula has been shown to have relatively good accuracy for patients with BMI ,18.5 kg/m 2 , CL CR estimation, and thus the estimation of the glomerular filtration rate, may therefore be biased. 41 Thirdly, there was substantial residual PK variability as expressed by the CEF u and CEF t additive error. An explanation may lie in drug dispensing and administration procedures, even though these procedures were observed when possible.
Although it is not unlikely that our study population's risk of CEF u underexposure is indicative of what happens to PK/PD in critically ill patients in general, extrapolations to non-SSA severely ill (ICU) patient populations should be made with caution, as underlying disease, as well as treatment aspects, including antibiotic infusion time and volume therapy, are likely to be different.
In conclusion, a one-compartment PPK model with non-linear protein binding adequately described the PK of CEF u and CEF t in a severely ill, non-ICU hospital population. Intermittent bolus dosing of the highly albumin-bound b-lactam ceftriaxone may lead to underexposure and can potentially pose a threat to a patient's health, especially when a patient's renal function is intact and when a q24h dosing regimen is used. Underexposure may also pose a threat to public health, as it is known to contribute to the emergence of antimicrobial resistance. These outcomes underscore a need for SSA antibiotic PK data against the background of locally derived MICs, so that well-known antibiotic drugs can be preserved for use in this region of the world. 
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